ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Other Current Liabilities

As of the most recent data (March 2026), LSPRU shows a other current liabilities of $3.4B. That compares with $-7.2B in the prior-year period — up 147.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LSPRU's other current liabilities is now $3.4B (was $-7.2B) — a 147.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) is outperforming or lagging.

Tracking LSPRU's other current liabilities over time shows whether ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) is scaling, shrinking, or reshaping that part of the business. The current reading is $3.4B That compares with $-7.2B in the prior-year period — up 147.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $3.4B) with ownership activity and broader fundamentals.